Indoco Remedies Ltd.

NSE: INDOCO | BSE: 532612 | ISIN: INE873D01024 | Industry: Pharmaceuticals
| Momentum Trap
293.0000 8.70 (3.06%)
NSE Aug 12, 2025 15:31 PM
Volume: 20,897
 

293.00
3.06%
Prabhudas Lilladhar
Indoco Remedies' (INDR) Q1FY26 EBITDA was largely in line. Though margins and regulated sales have recovered QoQ but they are still below its historical run-rate given elevated expenses and ongoing FDA issues. The warning letter issued for both units has restricted growth, however USFDA has allowed to resume supplies from 2 out of 4 lines. The company cited other expenses to remain elevated in the near term. Our FY26/FY27E EBITDA has been cut by 811% to factor in low margins. At CMP, the stock is trading at 3.9x EV/domestic...
Indoco Remedies Ltd. is trading below its 30 day SMA of 316.6
More from Indoco Remedies Ltd.
Recommended